Mind + Muscle

technical minds + legal muscle

Sterne Kessler Goldstein Fox
Jeremiah B. Frueauf

Mind + Muscle

Jeremiah B. Frueauf



Mr. Frueauf, a director in the Biotechnology/Chemical Group, counsels domestic and international clients on the preparation, prosecution, and management of complex worldwide patent portfolios.  He is also experienced in the research and preparation of freedom-to-operate, validity, infringement, and patentability analyses.

Mr. Frueauf has experience in various inter partes matters, including district court litigation, interference work before the U.S. Patent and Trademark Office, and Section 337 investigations before the U.S. International Trade Commission.  His work includes preparing strategy and analysis, motions practice, and case management for these matters.

Prior to joining Sterne Kessler, Mr. Frueauf was a Biologist at the National Cancer Institute where he studied the molecular signaling pathways related to programmed cell death using various molecular, biochemical, and proteomic technologies.  He also assisted in the administration of phase II clinical trials related to ovarian cancer. 

Mr. Frueauf's graduate work at Michigan State University as a member of the Starch Bio-Engineering Group focused on analysis of the structure/function relationships of the enzymes involved in starch and glycogen biosynthesis.  His work included successful alteration of the catalytic activity and inhibitor specificities of these enzymes to affect the recombinant production of starch or glycogen molecules.

Mr. Frueauf is a contributing author of Patent Office Litigation, a two-volume set focused on the new contested proceedings under the America Invents Act published in 2012 by Thomson Reuters Westlaw. This book examines how the proceedings interact with other aspects of patent procurement and enforcement, and delivers practical analysis and advice.    

Law Review Articles

Jeremiah B. Frueauf, "A Comparison of Section 337  Decisions at the ITC and Parallel District Court  Proceedings: The Commission's Decisions Affect  Dispositions at the District Courts," Vol. XXII 337  Rep., ITC Trial Law. Ass'n, 4th Ann. Summer Associate Edition 31 (2006).

Jeremiah B. Frueauf, Note, "Making Your Business Fly  Above Section 183: Fair Skies Following  Rabinowitz v. Commissioner," 59 Tax Law. 887  (2006).

Legal Publications

  • "Patent Term Extension Not A 1-Trick Pony for Animal Drugs," Jeremiah B. Frueauf, Aisha Haley, Deborah Sterling, Ph.D., Law360, August 2016
  • "USPTO Issues Subject matter Eligibility Update," Jeremiah B. Frueauf & Miklos Gaszner, Ph.D., Sterne, Kessler, Goldstein & Fox, August 2016
  • "Public Disclosure Grace Periods And the Trans-Pacific Partnership: Member States Seek Harmonization with the America Invents Act," Jeremiah B. Frueauf and Matthew A Smith, Bloomberg BNA's Patent, Trademark & Copyright Journal, February 2016
  • "Obama Administration Releases Much Anticipated Text of the Trans-Pacific Partnership Agreement," Jeremiah B. Frueauf & John M. Covert, Sterne, Kessler, Goldstein & Fox, November 2015
  • "Are Your Claims Patent Eligible," Jeremiah B. Frueauf, Deborah Sterling Ph.D. & Miklos Gaszner Ph.D., Biofuels International, July 2015
  • "Kimble v. Marvel -- Supreme Court quiets criticism of per se rule against post-patent royalties," Jeremiah B. Freuauf & Dr. Pratibha Khanduri, IP Watchdog, July 2015
  • "New International Searching Authority Available for Green Technology Companies," Peter A. Jackman and Jeremiah B. Frueauf, Sterne, Kessler, Goldstein & Fox Client Alerts, July 2015
  • "Practice Considerations Post Kimble v. Marvel," Jeremiah B. Frueauf and pratibha Khanduri, Ph. D., Sterne, Kessler, Goldstein & Fox, June 2015
  • "IPR: A Key to District Court's Assignor Estoppel Lock," Jeremiah B. Frueauf and Sana F. Hussain, IP Law360, May 2015
  • "America Invents: Immediate Changes to Patent Law Start Today," Eldora L. Ellison, Ph.D. and Jeremiah B. Frueauf, Sterne, Kessler, Goldstein & Fox, September 2011
  • "Ten Things to Know About Post-Grant Review Under the America Invents Act of 2011," Eldora L. Ellison, Ph.D. and Jeremiah B. Frueauf, Sterne, Kessler, Goldstein & Fox, September 2011
  • "Immediate Changes for Patent Practice Under the America Invents Act," Eldora L. Ellison, Ph.D. and Jeremiah B. Frueauf, Sterne, Kessler, Goldstein & Fox, September 2011
  • "Big Pharma and Section 337: The Next Frontier," Daniel E. Yonan, Keeto Sabharawl, Mark Fox Evens, and Jeremiah Frueauf, World Intellectual Property Review, August 2011
  • "Big Pharma and Section 337: The Next Frontier for Enforcement of Non-Orange Book Listed Pharmaceutical Drug Patents," Daniel E. Yonan, Keeto Sabharwal, Mark Fox Evens, and Jeremiah Frueauf, BNA's Pharmaceutical Law & Industry Report, August 2011

Technical Publications

Frueauf J. B., Ballicora M. A., and Preiss J. (2003)  “ADP-glucose Pyrophosphorylase from Potato Tuber.  Site-Directed Mutagenesis of Homologous  Aspartic Acid Residues in the Small and Large Subunits” Plant J. 33: 503-11.

Frueauf J. B., Ballicora M. A., and Preiss J. (2002)  “Alteration of Inhibitor Selectivity by Site-Directed Mutagenesis of Arg294 in the ADP-glucose  Pyrophosphorylase from Anabaena PCC 7120”  Arch. Biochem. Biophys. 400: 208-14.

Frueauf J. B., Ballicora M. A., and Preiss J. (2001)  “Aspartate Residue 142 is Important for Catalysis by ADP-glucose Pyrophosphorylase  from  Escherichia coli”J. Biol. Chem. 276: 46319- 25.

Ballicora M. A., Frueauf J. B., Fu Y. B., Schurmann P.,  and Preiss J. (2000) “Activation of the Potato Tuber ADP-glucose Pyrophosphorylase by  Thioredoxin” J. Biol. Chem. 275: 1315-20.

  • Admissions
      • Ohio

      • District of Columbia

      • United States Patent and Trademark Office

      • United States Supreme Court

      • U.S. Court of Appeals for the Federal Circuit

  • Education
    • J.D., Georgetown University

    • M.S., Biochemistry, Michigan State University

    • B.S., Chemistry/Biochemistry, Ohio University summa cum laude


    Unsolicited e-mails and information sent to Sterne, Kessler, Goldstein & Fox P.L.L.C. will not be considered confidential or privileged, may be disclosed to others, may not receive a response, and do not create an attorney-client relationship with Sterne Kessler.  If you are not already a client of Sterne Kessler, do not include any confidential information in this message.